Ascendis Pharma A/S clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   teACH · Navepegritide in Adolescents (12 - 18 Years of Age) With…teACH · Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia

   Enrollment closed, study ongoing

   Ascendis Pharma A/S·Phase 2· NCT06732895· Registry history of NCT06732895 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

2. Minor

   Weekly Lonapegsomatropin Compared to Daily Somatropin in Children…Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and · Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

   Trial sites expanded: 47 → 51 locations

   And 1 more change in the last 30 days

   Ascendis Pharma A/S·Phase 3· NCT07221851· Registry history of NCT07221851 on ClinicalTrials.gov (opens the registry)

   Updated Sep 30, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.